Featured News
COMPANY
Virginia Workforce Award to AMPEL BioSolutions
Virginia officials recognized AMPEL BioSolutions for their dedication to identifying, training, and retaining STEM-trained workers, especially in the area of precision medicine. The annual award recognizes Virginia employers who provide high-quality internships to students.
Charlottesville-area company receives praise for internship program
AMPEL BioSolutions, LLC. is being recognized by Virginia officials for its internship program. It is the only tech company in Charlottesville recognized this cycle. AMPEL says its priority is contributing to knowledge of the future. Interns are able to examine RNA, work on projects, and provide design support for doctors
Innovator-of-Year to AMPEL
CBIC of Virginia honored the team with “Innovator-of-the-Year” last night June 1st for the AMPEL Genomic Platform of RNA analytics and Machine Learning for dynamic disease management through flare prediction & personalized decision support for drug options. Charlottesville Business Innovation Council (CBIC) presented AMPEL’s “Innovator-of-the-Year” award at the University of Virginia Research Park.
Innovators, Educators, and Entrepreneurs Recognized at North Fork
2023 CBIC Awards recipients announced. On June 1, North Fork was the 2023 CBIC Awards Gala venue, where innovators, educators, and entrepreneurs came together to celebrate.
From Genomic Tests to AI Predictions: Dr. Amrie Grammer, Co-Founder of AMPEL BioSolutions, Joins BioTalk
Tune in to this exciting episode of BioTalk with Rich Bendis, featuring Dr. Amrie Grammer, Co-Founder of AMPEL BioSolutions. In this enlightening discussion, Dr. Grammer unveils the secrets behind AMPEL’s remarkable success in precision medicine, making this episode a must-listen.
Virginia Catalyst Awards $2 Million in Grants to Support Life Sciences in the Commonwealth
The critical mass achieved by these collaborations provides Virginia with competitive advantages over other states and has resulted in significant outside capital being invested to finance the commercialization of Virginia’s innovations and create significant high-paying jobs for the Commonwealth.
PLATFORM
Bloomberg’s “The Tape” Personalized Precision Medicine (Audio)
Dr. Amrie Grammer, co-founder of AMPEL BioSolutions, joins the show to discuss biotech and her company Hosted by Paul Sweeney and Matt Miller.
AMPEL BioSolutions’ Precision Medicine Breakthrough Predicts Drug Options with RNA Analytics & Machine Learning
AMPEL BioSolutions today announces a breakthrough in precision and personalized medicine that could modernize the way doctors treat patients across a wide variety of diseases including autoimmunity, infectious disease and cancer.
MI/AL for Diagnosis & Prognosis
Presentation by Amrie Grammer, Ph.D, COO/CSO, AMPEL BioSolutions at the Precision Medicine World Conference on June 28, 2022
PRODUCTS
AMPEL BioSolutions Developing Molecular Test to Predict Kidney Damage in Lupus Nephritis Patients
According to the company, the test identifies molecular markers in kidney biopsy samples of LN patients, which can help reveal patients’ disease stage. This information, in turn, could help those pharmaceutical companies who have more than 45 LN drugs in development enroll patients in clinical trials with greater precision, AMPEL said.Â
This New Blood Test For Fibromyalgia Could Identify Your Best Treatment Options
Different from the FM/a blood test used for diagnosis, this new blood test for Fibromyalgia may be the key to your treatment plan.
AMPEL BioSolutions’ Breakthrough Predicts Drug Options to Slow End Stage Renal Disease
CLICK TO VIEW ORIGINAL ARTICLE > CHARLOTTESVILLE, Va., March 1, 2023 /PRNewswire/ — AMPEL BioSolutions today announced a genomic precision medicine test for chronic kidney diseases, such as Lupus Nephritis, that could save lives by predicting kidney damage before...
AMPEL BioSolutions’ Breakthrough Predicts Drug Options to Slow End Stage Renal Disease
CLICK TO READ ARTICLE > AMPEL BioSolutions announced a genomic precision medicine test for chronic kidney diseases, such as Lupus Nephritis, that could save lives by predicting kidney damage before it is irreversible and providing decision support for prophylactic...
New test to identify, treat kidney disease
CLICK TO READ ARTICLE & VIEW VIDEO > By Felicity Taylor CHARLOTTESVILLE, Va. (CBS19 NEWS) -- A local company says it has discovered a new way to identify and treat kidney disease. AMPEL BioSolutions is a precision medicine company that studies RNA and gene...
AMPEL BioSolutions’ Breakthrough Predicts Drug Options to Slow End Stage Renal Disease
CLICK TO VIEW ARTICLE > CHARLOTTESVILLE, Va., March 1, 2023 /PRNewswire/ -- AMPEL BioSolutions today announced a genomic precision medicine test for chronic kidney diseases, such as Lupus Nephritis, that could save lives by predicting kidney damage before it is...
PARTNERS
Reuters – Google Webinar Featuring AMPEL for Pharma Partnering
Reuters Events webinar with AMPEL, Google Cloud, Novartis, Asklepios and Pfizer to learn how data-driven innovation is reshaping clinical trials and paving the way towards faster drug discovery, more diverse patient enrolment and improved patient retention.
AMPEL’s AL/ML in Clinical Trial Design
Panel Presentation at the Precision Medical World Conference, June 29, 2022
Podcast on Lupus Diagnosis & Treatment
An Interview with Dr. Amrie Grammer on Dartmouth's "No Scrubs" Podcast